Tesamorelin
Single peptide · 5 mg · lyophilised · coming soon. Research use only — not for human consumption.
Single peptide · 5 mg · lyophilised · coming soon. Research use only — not for human consumption.
One email when Tesamorelin goes on sale · no marketing list · UK delivery included on every order · Pay by card
Synthetic 44-residue peptide: hGRF(1–44) amide with an N-terminal trans-3-hexenoyl group. Planned as a 5 mg listing to the same standard as the rest of the catalogue: lyophilised powder in a crimp-sealed glass vial, held in UK stock, dispatched tracked on working days with UK delivery included in the price.
Tesamorelin is a synthetic peptide of 44 amino acid residues. Its sequence is that of human growth hormone-releasing factor, hGRF(1–44), amidated at the C-terminus, with a trans-3-hexenoyl group attached to the N-terminal tyrosine; that acyl group is what distinguishes it from the unmodified 44-residue sequence, and it is why the material is written in the literature as trans-3-hexenoyl-hGRF(1–44)-NH2. Its identifiers are given in the specification table: CAS 218949-48-5, molecular formula C221H366N72O67S and a molar mass of approximately 5135.9 g/mol for the free peptide.
It sits in the same structural family as the CJC-1295 No DAC already in the catalogue, which is a 29-residue modified GRF(1–29) sequence; tesamorelin is the full-length 44-residue sequence with a different N-terminal modification. Both are supplied, or planned, as lyophilised powder in a crimp-sealed glass vial. As with every material we list, the planned fill weight of 5 mg is the mass of powder in the vial, not a statement of net peptide content; the distinction is explained in peptide purity versus net peptide content.
Tesamorelin is not yet on sale. It is listed so that laboratories in the United Kingdom can see what is planned and register interest; when it is in UK stock we send one email to say so, with the price, and nothing else. When it goes on sale it will be supplied on the same terms as every other material here: the price shown will be the total payable with UK delivery included, dispatched by Royal Mail Tracked 24 in unbranded packaging, with an order placed before 14:00 on a working day leaving that day where stock allows. Dispatch detail is on the shipping page. We supply research organisations, educational and commercial laboratories, and individuals purchasing for legitimate research.
Tesamorelin will be supplied as a lyophilised powder in a crimp-sealed glass vial, to be stored at −20 °C and protected from light. The sequence contains one methionine (Met27), so oxidation of that side chain is the pathway to watch once the cake is exposed to air or moisture, and it carries several asparagine and glutamine residues, which are the sites of deamidation in solution. Both are dormant while the powder stays dry and cold, which is why the seal matters more than anything else; the reasoning is set out in lyophilised peptide storage and stability.
Tesamorelin is listed by NorthScientific strictly for laboratory research use. It is not a licensed medicine and has not been evaluated or approved by the MHRA; it is not a food, cosmetic or supplement; and it is not for human or veterinary consumption in any form. We provide no dosing, protocol or outcome guidance of any kind, and nothing on this page, in our guides or in correspondence should be read as such.
No. NorthScientific lists Tesamorelin for laboratory research only; it is not for human or veterinary consumption in any form. We give no dosing or protocol guidance, and nothing on this page should be read as such.
We list it now so that laboratories can register interest, and we email once, when it is in UK stock and on sale. No date is promised: it goes on sale when supply meets the same standard as the rest of the catalogue, and the price is published then.
It is a six-carbon acyl group attached to the N-terminal tyrosine of the peptide. The rest of the molecule is the 44-residue hGRF sequence with a C-terminal amide. The group is part of the material's chemical identity, which is why we state it in the specification rather than describing tesamorelin simply as “GRF(1–44)”.
Both derive from the GRF sequence. CJC-1295 No DAC is a 29-residue sequence, GRF(1–29), with four amino-acid substitutions. Tesamorelin is the full 44-residue sequence, unsubstituted, with the hexenoyl group on the N-terminus and an amide at the C-terminus. They are listed separately because they are different molecules with different formulae and masses.
Not necessarily. The planned 5 mg is the fill weight of lyophilised powder in the vial; how much of that is peptide depends on the salt form and residual moisture and would be reported on an analysis as net peptide content. We do not publish an analysis for this material, so read the figure as fill weight.
